# Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

> **NCT03550313** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 565 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Multivalent
- **BIOLOGICAL:** Prevnar 13

## Key facts

- **NCT ID:** NCT03550313
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-01
- **Primary completion:** 2020-11-05
- **Final completion:** 2020-11-05
- **Target enrollment:** 565 (ACTUAL)
- **Why stopped:** Study vaccinations and blood draws were halted due to adequacy of a smaller dataset and study feasibility issues. It was not based on any safety concerns.
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03550313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03550313, "Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03550313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*